Greg Bosch brings over 30 years in the life science and healthcare sectors with leadership of commercial, operations, research and clinical development teams across the US and Europe. His passion is to advance technologies and therapeutic solutions to improve patient care, treatments and outcomes. His broad general management experience spans the pharmaceutical, biologics and medical device segments. Greg has grown businesses organically as well as through acquiring public and private companies and helped fund companies through both private financings as well as taking a company public through an IPO.

Greg is currently Chairman and CEO of Panavance Therapeutics Inc., a clinical stage oncology company developing its novel small molecule asset to address multiple cancer targets with pancreatic ductal adenocarcinoma and ovarian cancer as its top priorities. Greg led the creation of Panavance as a spin out of the Geistlich group in 2021. Prior to Panavance, Greg was Chief Executive Officer of Geistlich Pharma North America from 2012 to 2021, where he led a cross functional team which established Geistlich as the US market leader in the biomaterial and regenerative medicine dental field by building strong relationships with clinicians in both the periodontist and oral & craniofacial surgery professions.

During his tenure, he also launched the Osteo Science Foundation, the Geistlich company’s 501(c)(3), established to support research and education in regenerative medicine for dentistry. He also supported Geistlich’s US biomaterials businesses in the woundcare and orthopedic segments. While at Geistlich, Greg also led the company’s global oncology program and was responsible for the team developing its proprietary small molecule drug compound GP-2250 from early R&D through to the first clinical studies.

From 2004 to 2012, Greg was the President and Chief Executive Officer of PuriCore PLC, a company focused on a novel antimicrobial technology. Greg led the private, venture-backed company through a successful IPO raising £30 (USD 50) million on the London FTSE. In 2006 he was named CEO of the year in the Philadelphia Life Sciences sector. Prior to his experience with PuriCore, he held roles of increasing responsibility at American Hospital Supply / Baxter International including General Manager of the BioSurgery Business which pioneered a new industry sector of companies focusing on biomaterials and biologics to be utilized across all surgical applications. Under Greg’s leadership, Baxter’s BioSurgery business grew from $35 million to $225 million within 5 years. During his career at Baxter, Greg was also Vice President of Strategic Planning and Assistant to the President, where he was based in Zurich, Switzerland and Vienna, Austria helped lead the integration and management of Immuno AG for five years.

Greg currently serves on the Board of Kibow Biotech, Inc. Greg earned his undergraduate degree in Public Policy from Duke University and an MBA from DePaul University’s Kellstadt Graduate School of Business.

E-Mail: Greg.Bosch@panavance.com

Mr. Eklund is deeply interested in science and business innovation and passionate about converting that knowledge for the benefit of patients.

He has a strong track record in a variety of settings; both the US and European markets - private and public - and in small biotechs as well as large multinationals.

Until 2019, Mr. Eklund served as Chief Commercial Officer of Swiss listed Vifor Pharma (now CSL Vifor). Vifor is a specialty pharma company and the global leader in Iron Deficiency, Nephrology and Cardiorenal therapies. In this role, he oversaw the rapidly growing global business operations with wholly owned subsidiaries in 30+ markets. The role also entailed leading numerous partnerships, including those with Takeda, UCB, Merck KGaA, Novartis/Sandoz and Daiichi Sankyo in the Pharmerging markets and the US, China and Japan.

During his tenure at Vifor, Mr. Eklund was also a Member of the Board of Directors for Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care).

Between 2005-2014, he was member of the executive team at Organogenesis Inc, a Boston-based global leader in regenerative medicine/cell therapy and the world’s second oldest independent biotech company. During his decade with Organogenesis, the company experienced compounded annual growth of 25%. At Organogenesis, Mr. Eklund built and led a team that gained FDA Panel approval (BLA) for GINTUIT(TM), the first ever manufactured allogeneic cell therapy to be approved by the Biologics Division of the FDA (CBER) in 2013. This approval was later awarded nomination “Best Biotech Product 2013” by Prix Galien.

Prior to his move to the US in 2004, from 2002 to 2004, he was the General Manager for Sanofi (Aventis) in Switzerland. Through a strong focus on vision, strategy, culture and execution, his team turned around the company's Swiss business, making it the fastest growing Top 10 pharmaceutical company in that market.

Prior to joining Sanofi (Aventis), from 1994 to 2002, Mr. Eklund spent nearly a decade at Novartis in various local, regional and global roles.

He hold a B.Sc (Business Administration) and a M.Sc. (Economics) from the Swedish School of Economics and Business Administration in Helsinki, Finland.

E-Mail: dario.eklund@gmail.com